peramivir and Cytokine-Release-Syndrome

peramivir has been researched along with Cytokine-Release-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for peramivir and Cytokine-Release-Syndrome

Article	Year
Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects. Frontiers in immunology, 2022, Volume: 13 Coronavirus Disease 2019 (COVID-19) infected by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been declared a public health emergency of international concerns. Cytokine storm syndrome (CSS) is a critical clinical symptom of severe COVID-19 patients, and the macrophage is recognized as the direct host cell of SARS-CoV-2 and potential drivers of CSS. In the present study, peramivir was identified to reduce TNF-α by partly intervention of NF-κB activity in LPS-induced macrophage model. Topics: Acids, Carbocyclic; Animals; COVID-19 Drug Treatment; Cytokine Release Syndrome; Guanidines; Humans; Leukocytes, Mononuclear; Mice; SARS-CoV-2; Tumor Necrosis Factor-alpha	2022

Article

Year

Peramivir, an Anti-Influenza Virus Drug, Exhibits Potential Anti-Cytokine Storm Effects.

Frontiers in immunology, 2022, Volume: 13

Coronavirus Disease 2019 (COVID-19) infected by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been declared a public health emergency of international concerns. Cytokine storm syndrome (CSS) is a critical clinical symptom of severe COVID-19 patients, and the macrophage is recognized as the direct host cell of SARS-CoV-2 and potential drivers of CSS. In the present study, peramivir was identified to reduce TNF-α by partly intervention of NF-κB activity in LPS-induced macrophage model.

Topics: Acids, Carbocyclic; Animals; COVID-19 Drug Treatment; Cytokine Release Syndrome; Guanidines; Humans; Leukocytes, Mononuclear; Mice; SARS-CoV-2; Tumor Necrosis Factor-alpha

2022